Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:09 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

NCT05215951 · AstraZeneca · PHASE2 · terminated · last registry update 2025-10-15 · Non-small cell lung cancer · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Kind	Quote	Our category	Source
Stated	“Enrollment delay study timeline seriously.”	Open Targets' class: insufficient enrollment	Registry record, AstraZeneca

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against EGFR in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

Internal portfolio and board discussions
Unpublished trial data and interim analyses
Terms of any partner or licence decision